Healthcare Resource Utilization and Associated Costs in Patients with Advanced Melanoma Receiving First-Line IpilimumabReportar como inadecuado




Healthcare Resource Utilization and Associated Costs in Patients with Advanced Melanoma Receiving First-Line Ipilimumab - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Background: To describe healthcare costs, excluding ipilimumab drugcosts, in patients with advanced melanoma receiving ipilimumab in the UScommunity practice setting. Methods: This was a retrospective chart review ofunresectable stage III-IV melanoma patients who received first-line ipilimumabmonotherapy between 04-2011 and 09-2012. Healthcare resource utilization includedinpatient, emergency, specialist and hospice visits, laboratory tests,radiation, surgeries, and nursing home stays. Publicly available US unit costswere applied to each resource type to estimate costs, which were analyzed bytime periods: during ipilimumab treatment, post-ipilimumab treatmentpost-regimen, and within 90 days prior to death pre-death. Generalizedlinear mixed models were used to explore cost predictors during the treatmentperiod, on a per-dose-interval basis, defined as the time between ipilimumabdoses. Results: Data were abstracted from 273 patient charts at 34 sites.Excluding ipilimumab drug costs, total monthly costs during the treatmentregimen, post-regimen, and pre-death periods were $690, $2151, and $5123, respectively.Total healthcare costs were 27 times higher during dose intervals with a grade3-4 adverse event compared with intervals without a grade 3-4 adverse event. EasternCooperative Oncology Group performance status ≥ 2 vs 0 was also associatedwith significantly higher cost per dose interval. Conclusions: In thispopulation, monthly costs exclusive of drug were significantly lower during thetreatment period than in subsequent periods. Unfavorable ECOG PS was associatedwith significant increases in cost per dose interval. Grade 3-4 adverse eventswere associated with a marked increase in healthcare costs, but occurred in asmall proportion of dose intervals.

KEYWORDS

Healthcare Resource Utilization, Ipilimumab, Melanoma

Cite this paper

Tarhini, A. , Corman, S. , Rao, S. , Margolin, K. , Ji, X. , Mehta, S. and Botteman, M. 2015 Healthcare Resource Utilization and Associated Costs in Patients with Advanced Melanoma Receiving First-Line Ipilimumab. Journal of Cancer Therapy, 6, 833-840. doi: 10.4236-jct.2015.610091.





Autor: Ahmad Tarhini1, Shelby L. Corman2, Sumati Rao3*, Kim Margolin4, Xiang Ji2, Sonam Mehta2, Marc F. Botteman2

Fuente: http://www.scirp.org/



DESCARGAR PDF




Documentos relacionados